Compare Moderna, Inc. (MRNA) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Symbotic Inc — how do they compare? Moderna, Inc. trades at $196.55 (market cap $78.65B), while Symbotic Inc trades at $42.67 (market cap $5.46B). The key difference: Moderna, Inc. is far larger — about 14.4× Symbotic Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Symbotic Inc for 23 Days on average.
| MRNA | SYM | |
|---|---|---|
Market Cap | $78.65B | $5.46B |
Volume | 37,373,437 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $203.46 | $87.30 |
52-Week Low | $22.36 | $38.22 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $74.80B | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported negative net income of -$16.94M for 2025 despite $2.25B revenue, though 2026 projections show improvement to $8M net profit. Analysts maintain a buy consensus with a $60.33 price target, representing 39% upside potential from current levels.
SYM presents growth potential with a massive $22.5B backlog and expanding robotics/AI market, but faces significant customer concentration risk (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1.05, though high EV/EBITDA of 74.05 suggests premium valuation relative to current earnings power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
